Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Xi'an Jiaotong UniversityNo recent work listed

Liang Cheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7270-5398. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2017: 2 papers · 2018: 10 papers · 2019: 5 papers · 2020: 1 paper

Papers 18

  1. NAF-1 Inhibition by Resveratrol Suppresses Cancer Stem Cell-Like Properties and the Invasion of Pancreatic Cancer. First author DOI 10.3389/fonc.2020.01038↗
  2. Mouse-Derived Allografts: A Complementary Model to the KPC Mice on Researching Pancreatic Cancer In Vivo. Co-author DOI 10.1016/j.csbj.2019.03.016↗
  3. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Co-author DOI 10.1111/cpr.12514↗
  4. High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer. Co-author DOI 10.1186/s13046-019-1288-7↗
  5. Hypoxia-inducible Factor-1α Mediates Hyperglycemia-induced Pancreatic Cancer Glycolysis. Co-author DOI 10.2174/1871520619666190626120359↗
  6. Betulinic acid inhibits stemness and EMT of pancreatic cancer cells via activation of AMPK signaling. Co-author DOI 10.3892/ijo.2018.4604↗
  7. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.27266↗
  8. Hyperglycemia aggravates microenvironment hypoxia and promotes the metastatic ability of pancreatic cancer. Co-author DOI 10.1016/j.csbj.2018.10.006↗
  9. Metformin suppresses tumor angiogenesis and enhances the chemosensitivity of gemcitabine in a genetically engineered mouse model of pancreatic cancer. Co-author DOI 10.1016/j.lfs.2018.07.046↗
  10. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. Co-author DOI 10.1016/j.yexcr.2018.07.041↗
  11. Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways. Co-author DOI 10.1155/2018/9482018↗
  12. Inhibiting YAP expression suppresses pancreatic cancer progression by disrupting tumor-stromal interactions. Co-author DOI 10.1186/s13046-018-0740-4↗
  13. Overexpression of Gremlin 1 by sonic hedgehog signaling promotes pancreatic cancer progression. First author DOI 10.3892/ijo.2018.4573↗
  14. Itraconazole inhibits invasion and migration of pancreatic cancer cells by suppressing TGF-β/SMAD2/3 signaling. First author DOI 10.3892/or.2018.6281↗
  15. Metformin suppresses the invasive ability of pancreatic cancer cells by blocking autocrine TGF‑β1 signaling. Co-author DOI 10.3892/or.2018.6518↗
  16. Norepinephrine enhances cell viability and invasion, and inhibits apoptosis of pancreatic cancer cells in a Notch‑1‑dependent manner. Co-author DOI 10.3892/or.2018.6696↗
  17. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Co-author DOI 10.1002/1878-0261.12116↗
  18. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Co-author DOI 10.1186/s12943-017-0701-0↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 18 shared papers, 2017–2020 · strength 1.39
  2. Weikun Qian · 16 shared papers, 2017–2020 · strength 1.24
  3. Wanxing Duan · 13 shared papers, 2017–2020 · strength 0.99
  4. Cancan Zhou · 13 shared papers, 2017–2019 · strength 0.95
  5. Jiguang Ma · 12 shared papers, 2017–2020 · strength 0.93
  6. Junyu Cao · 12 shared papers, 2017–2019 · strength 0.90
  7. Bin Yan · 11 shared papers, 2017–2019 · strength 0.81
  8. Zhengdong Jiang · 10 shared papers, 2017–2019 · strength 0.73
  9. Ke Chen · 9 shared papers, 2017–2019 · strength 0.64
  10. Liankang Sun · 8 shared papers, 2017–2019 · strength 0.57
  11. Qinhong Xu · 6 shared papers, 2018–2020 · strength 0.49
  12. Jie Li · 6 shared papers, 2017–2019 · strength 0.43
  13. Xuqi Li · 5 shared papers, 2018–2019 · strength 0.40
  14. Ying Xiao · 4 shared papers, 2018–2020 · strength 0.35
  15. Erxi Wu · 4 shared papers, 2018–2020 · strength 0.33
  16. Zheng Wang · 4 shared papers, 2018–2019 · strength 0.32
  17. Zheng Wu · 3 shared papers, 2019 · strength 0.26
  18. Tao Qin · 3 shared papers, 2018–2020 · strength 0.26
  19. Tao Qin · 3 shared papers, 2018–2019 · strength 0.24
  20. Jianjun Lei · 3 shared papers, 2018–2019 · strength 0.23
  21. Liang Han · 2 shared papers, 2018 · strength 0.16
  22. Lucas Wong · 1 shared paper, 2020 · strength 0.10
  23. Zheng Wang · 1 shared paper, 2020 · strength 0.10
  24. Wěi Li · 1 shared paper, 2019 · strength 0.09
  25. Xin Chen · 1 shared paper, 2019 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.